Sushil Gupta
Pulmonary Disease · New Haven, CTNPI 1174954960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $967 and has fallen 67.7% since, to $312 in 2025.
Across 171 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$681
- Harmony Biosciences LLC$581
- Merck$430
- Boehringer Ingelheim$392
- AstraZeneca$390
- Jazz Pharmaceuticals Inc.$195
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,20099%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 36 | $681 |
| Harmony Biosciences LLC | 27 | $581 |
| Merck | 18 | $430 |
| Boehringer Ingelheim | 23 | $392 |
| AstraZeneca(2 entities) | 7 | $390 |
| Jazz Pharmaceuticals Inc. | 12 | $195 |
| Mylan Specialty L.p. | 10 | $187 |
| Lilly USA, LLC | 3 | $161 |
| Vanda Pharmaceuticals Inc. | 9 | $127 |
| Itamar Medical Inc | 2 | $127 |
| Seapearl East, Inc | 1 | $126 |
| Amarin Pharma, Inc. | 1 | $125 |
| Olympus America Inc. | 1 | $120 |
| Philips North America LLC | 5 | $119 |
| Axsome Therapeutics, Inc. | 1 | $118 |
| Fisher & Paykel Healthcare Inc | 1 | $101 |
| Eisai Inc. | 6 | $89 |
| Resmed Corp | 2 | $66 |
| Aytu Biopharma, Inc. | 2 | $38 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| Circassia Inc. | 1 | $19 |
| Sanofi | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$503
- FARXIGA$125
- Vascepa$125
- JARDIANCE$124
- Wakix$121
- EVIS EXERA$120
- SUNOSI$118
- WatchPATONE$107
- SOLIRIS$105
- FASENRA$105
- STEGLATRO$103
How this compares
$4,248 in reported general payments places this provider in the 70th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$1.2M
- Michael ImevboreNew Haven$323K
- Naftali KaminskiNew Haven$180K
- Lauren CohnNew Haven$134K
- Erica HerzogNew Haven$74K
- Mridu GulatiNew Haven$53K
- Jennifer PossickNew Haven$48K
- Carolyn RochesterNew Haven$29K
- Maor SaulerNew Haven$18K
- Jonathan KoffNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.